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Abstract
Approximately 5–10% of cystic ﬁbrosis (CF) patients develop multilobular cirrhosis during the ﬁrst decade of life. Most CF patients
later develop signs of portal hypertension with complications, mainly variceal bleeding. Liver failure usually occurs later, after the paediatric
age. Annual screening for liver disease is recommended to detect pre-symptomatic signs and initiate ursodeoxycholic acid therapy, which
might halt disease progression. Liver disease should be considered if at least two of the following variables are present: abnormal physical
examination, persistently abnormal liver function tests and pathological ultrasonography. If there is diagnostic doubt, a liver biopsy is
indicated. All CF patients with liver disease need annual follow-up to evaluate the development of cirrhosis, portal hypertension or liver
failure. Management should focus on nutrition, prevention of bleeding and variceal decompression. Deterioration of pulmonary function is an
important consideration for liver transplantation, particularly in children with hepatic dysfunction or advanced portal hypertension.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Cystic ﬁbrosis (CF) is the most common life-limiting
autosomal recessive disease of the Caucasian population,
with an incidence of approximately 1 in every 3000 live
births worldwide [1]. It is a multiorgan disease affecting
mainly the lungs, pancreas, sweat glands, and in males the
Wolfﬁan ducts. Liver Disease associated with Cystic Fibrosis
(CFLD) is a well known complication. Long-term follow-up
of different cohorts of CF patients carefully monitored for
hepatic involvement indicates a cumulative incidence of liver
disease ranging between 27% and 35%, without incident cases
after the age of 18 years [2,3]. In a prospective study, the
incidence of CFLD was 2.5 per 100 patient-years during the
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ﬁrst 10 years of life (95% CI: 1.8–3.3), declining sharply
during the second decade [2]. Approximately 5 to 10% of all
CF patients will develop multilobular cirrhosis during the ﬁrst
decade of life [2,3]. Most of these will develop signs of portal
hypertension (PHT), and present with related complications
during the second decade, mainly variceal bleeding [4,5].
Liver failure is usually a late event that occurs rarely in the
paediatric age group [4]. Liver cirrhosis remains the single
most important non-pulmonary cause of death, accounting for
2.5% of overall CF mortality [6].
The wide spectrum of hepatobiliary disease in CF patients
includes speciﬁc alterations due to the underlying cystic
ﬁbrosis transmembrane conductance regulator (CFTR) defect,
lesions of iatrogenic origin, as well as the effects of extra-
hepatic disease [7] (Table 1).
The typical hepatic lesion of CF, related to the CFTR defect
in cholangiocytes, is focal biliary cirrhosis, which results
from biliary obstruction and progressive periportal ﬁbrosis.
This is the most clinically relevant CF-associated hepatic
problem, since extension of the initially focal ﬁbrogenic
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Table 1
Hepatobiliary manifestations in CF (modiﬁed from Kelly [8])
Type of lesion Clinical manifestation Frequency (%)
Speciﬁc alterations ascribable to the underlying CFTR defect Focal biliary cirrhosis 20–30
Multilobular biliary cirrhosis 10
Portal hypertension 2–5
Neonatal cholestasis <10
Sclerosing cholangitis often silent
Microgallbladder 30
Cholelithiasis 15
Lesions of iatrogenic origin Hepatic steatosis 25–60
Drug hepatotoxicity undeﬁned
Lesions reﬂecting the effects of a disease process that occurs outside the liver Hepatic congestion rare
Common bile duct stenosis* rare
*Might be part of sclerosing cholangitis disease.
process may lead to multilobular biliary cirrhosis, portal
hypertension and related complications [9]. The reasons why
the distribution of hepatic lesions is focal at least in the
early stages and why a minority of CF patients develop overt
liver disease (i.e. multilobular cirrhosis), remain unknown.
No speciﬁc CFTR mutations have been associated with the
presence and severity of liver disease. The liver phenotype
in CF patients with the same CFTR genotype is variable,
suggesting that environmental factors or modiﬁer genes might
be important in the development of CFLD. Of different
candidate genes (SERPINA1, ACE, TGFB1, MBL2, GSTP1),
only the SERPINA1 Z allele was found to be strongly
associated with CFLD and portal hypertension [10].
Steatosis is a common hepatic lesion associated with CF
that does not seem, however, to be directly related to the CF
secretory defect (Table 1). Massive steatosis has become infre-
quent due to earlier diagnosis and to more appropriate nutri-
tional care. Mild steatosis is more common and has been asso-
ciated with selective nutritional deﬁciencies including speciﬁ-
cally essential fatty acids and altered phospholipid metabolism
in CF [3,11]. Steatosis has been considered a benign condition
in CF, without a proven relationship to the subsequent devel-
opment of cirrhosis. However, the available data on the role
of nonalcoholic steatohepatitis as a cause of cirrhosis in adults
may lead to reconsideration of this issue in CF patients [12].
Typical cholangiographic abnormalities of the intrahepatic
bile ducts compatible with sclerosing cholangitis, have been
reported in children [13] and in the majority of adult patients
with CFLD [14]. Such lesions have been considered to be
the expression of an inﬂammatory process involving the bile
ducts, accumulation of proteins and mucus, and compression
of intrahepatic bile ducts induced by ﬁbrosis. Using magnetic
resonance cholangiography (MR cholangiography), bile duct
abnormalities have also been documented in a signiﬁcant
proportion of CF patients without clinically apparent liver
disease [15].
Current evidence suggests that liver disease in CF results
from bile duct obstruction related to the CFTR defect in
cholangiocytes, toxic retention leading to peribiliary ﬁbrosis
[9,16] and increased amounts of sludge in the biliary tract,
leading to the development of microgallbladder and variability
of the biliary ductular lumen. Based on this pathophysiologi-
cal hypothesis, ursodeoxycholic acid (UDCA), a hydrophilic
and choleretic bile acid, has been widely used in CF patients
and shown to improve liver function tests, biliary drainage,
early ultrasonographic changes in the liver and even liver
histology [17–21]. UDCA remains to date the only available
treatment that may prevent or halt the progression of liver
disease in CF patients. Therefore, asymptomatic patients with
early stage liver disease are more likely to beneﬁt from
UDCA administration. No signiﬁcant side effects related to
the long-term use of this drug have been reported.
Neonatal screening for CF is now routine in many Euro-
pean countries. However, recognition of CF patients at risk
of developing liver disease remains a major clinical issue. No
genotype-phenotype correlation has been demonstrated [2,22].
Several factors have been recognized to be signiﬁcantly asso-
ciated with liver disease, including meconium ileus, the role
of which as a predisposing factor to the development of CFLD
remains controversial [2,3,22–24].
Therefore, regular screening for CFLD is necessary to
detect pre-symptomatic signs of liver involvement in order to
initiate UDCA therapy. In CF patients who develop cirrhosis,
it is necessary to screen for complications related to PHT
(e.g. esophageal or gastric varices, hepatopulmonary and
portopulmonary syndromes) and for signs of liver failure.
Management should focus mainly on nutrition, prevention of
bleeding and variceal decompression.
2. Diagnosis of CF associated liver disease
Evidence of liver disease in CF patients is often subclinical
until pathological changes are diffuse and pronounced.
Most often patients remain asymptomatic, without jaun-
dice and pruritus, even when multilobular cirrhosis develops.
The most common clinical presentation of liver disease is
the ﬁnding of hepatomegaly on routine physical examina-
tion, often but not always associated with abnormalities of
liver biochemistry. Hepatomegaly may also result from fatty
inﬁltration of the liver or focal biliary ﬁbrosis.
The rate of progression of liver disease differs markedly
from one patient to another, but most often diagnosis of
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multilobular cirrhosis becomes clinically evident at the end
of the ﬁrst decade of life, associated with signs of portal
hypertension. The liver is ﬁrm and nodular and its enlargement
may be limited to one lobe, particularly to the left lobe that
protrudes centrally, often associated with splenomegaly that
may cause abdominal discomfort or pain. Attention should
be paid to the presence of peripheral signs of chronic liver
disease, including spider naevi, palmar erythema, clubbing,
jaundice, oedema, distension of abdominal wall veins and
ascites, although these are late signs.
Since a sensitive and speciﬁc test to evaluate biliary cell
function is not yet available, early diagnosis of CFLD requires
regular clinical examination, biochemical tests and imaging
techniques.
2.1. Diagnostic work-up: evidence and limitations
2.1.1. Liver function tests
Biochemical abnormalities (serum liver enzymes) are fre-
quently mild or intermittently present and have low sensitivity
and speciﬁcity; abnormalities usually do not correlate with
histological ﬁndings [25]. Common ﬁndings include intermit-
tent rise in serum transaminases (aspartate aminotransferase
(AST) and alanine aminotransferase (ALT)) and/or increased
serum levels of alkaline phosphatase (ALP) and gamma-
glutamyl transferase (GGT). Not infrequently, CF patients
with multilobular biliary cirrhosis may have completely nor-
mal liver biochemistry. Isolated elevation of transaminases
with normal concentrations of enzyme related to cholesta-
sis (GGT and AP) may suggest the presence of steatosis,
which should be adequately recognized and followed-up, after
correction of nutritional deﬁciencies, if present. An isolated
increase of ALP with normal GGT and transaminases is not
speciﬁc to liver disease in growing children. In addition, non-
speciﬁc biochemical abnormalities are very common during
the ﬁrst year of life and have been documented in more
than 50% of infants with CF, with complete normalization
in most cases within 2–3 years of age. A minority of in-
fants may even present with neonatal cholestasis, particularly
those with meconium ileus, and other conditions enhanc-
ing the risk of cholestasis, i.e., total parenteral nutrition or
abdominal surgery. However, cholestasis generally resolves
spontaneously over the ﬁrst months of life and has no impact
on future development of liver disease [26].
Occasional biochemical abnormalities may also occur as a
result of drug treatment or infection. Other causes of acute or
chronic cytolysis should be excluded (Table 2).
New and potentially useful tests have been proposed,
including serum markers of ﬁbrogenesis (e.g. collagen VI and
prolyl hydroxylase) [27]. However, their use remains limited
and their diagnostic value needs to be further evaluated.
2.1.2. Ultrasound scan
Ultrasonography (US) of the hepatobiliary system with
Doppler measurements of hepatic ﬂow is non-invasive and
inexpensive. Evidence has been provided that US is more sen-
sitive for CFLD than clinical and biochemical abnormalities
Table 2
Causes of acute or chronic liver disease in CF patients showing hepatic
abnormalities
Condition Investigation
Acute/chronic viral hepatitis Serology for HAV, HBV, HCV, EBV,
CMV, adenovirus, HHV 6, parvovirus
α1 antitrypsin deﬁciency Serum α1 antitrypsin level, including
phenotype
Autoimmune hepatitis Non-organ speciﬁc autoantibodies
(SMA, anti-LKM1, LC1)
Celiac disease Total IgA, IgA anti-tissue
transglutaminase




Iron, Ferritin, Transferrin binding
capacity
Other causes of steatosis Malnutrition, diabetes, obesity
Abbreviations: HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepati-
tis C virus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV6, herpes
hominis virus type 6; SMA, smooth muscle antibody; LKM1, liver kidney
microsomal type 1, LC1, liver cytosol type 1.
[28,29]. Abnormal echogenicity frequently precedes clinical
and biochemical manifestations of liver disease, suggesting
that routine US may be a valuable marker of early liver
disease in CF. A simple echographic scoring system based on
coarseness of liver parenchyma, nodularity of the liver edge
and increased periportal echogenicity has been proposed for
the identiﬁcation of patients with pre-cirrhotic liver disease
and their follow-up [30]. However, there is clearly intra and
interobserver variability in sonographic assessment of hepatic
echostructure. The positive predictive value of a normal ul-
trasound has been shown to be only 33%, with a sensitivity
of 57% [31]. Although US diagnosis of fatty inﬁltration of
the liver, of cirrhosis and portal hypertension is most often
accurate, a normal ultrasound does not preclude signiﬁcant
liver ﬁbrosis [31]. Therefore, diagnosis of early liver disease
cannot reliably be made on the basis of ultrasound alone.
2.1.3. Liver biopsy
Histological assessment represents the gold standard in the
diagnostic work-up of many chronic liver diseases. In CF,
it may provide important information on the predominant
type of lesion (steatosis or focal biliary cirrhosis) and the
extent of portal ﬁbrosis [25]. However, because of the
patchy distribution of lesions in CFLD, liver biopsy may
underestimate the severity of lesions and is not a routine
investigation in many units.
2.1.4. Transient elastography (Fibroscan)
Fibroscan is a new medical device that measures liver
stiffness in a non invasive, rapid, and reproducible way [32].
Liver stiffness has been shown to be closely related to liver
ﬁbrosis and validated for staging of ﬁbrosis in patients with
chronic liver diseases, especially hepatitis C [33]. Studies
in CF patients are in progress to conﬁrm its usefulness in
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diagnosing CFLD at an early stage and assess progression of
liver ﬁbrosis [34].
2.1.5. Abdominal computed tomography (CT) and magnetic
resonance imaging (MRI)
Both CT and MRI are useful to discriminate ﬁbrosis from
steatosis and to appreciate the nature of focal lesions (i.e.
focal steatosis, hemangioma, focal nodular hyperplasia, hep-
atocarcinoma). MRI tends to replace CT, especially in older
children who do not need sedation, since it does not expose
the patient to radiation and allows imaging of the biliary tree.
MR cholangiography is not routinely performed in the CF
paediatric population, but could be useful for early detection
of intrahepatic biliary tract involvement that may contribute
to the development of biliary cirrhosis, especially in children
with symptoms (i.e. jaundice, abdominal pain) or signs (i.e.
dilated bile ducts at US) suggestive of sclerosing cholangitis,
distal stenosis of the common bile duct or choledocholithiasis.
Indeed, the usefulness of MR cholangiography, which can
substitute for endoscopic retrograde cholangiopancreatogra-
phy (ERCP), has been highlighted in one study on CF adults,
showing cholangitic lesions in all patients with liver disease
and in half of those without apparent liver disease [15].
2.1.6. Cholangiography
Percutaneous transhepatic cholangiography and endo-
scopic retrograde cholangiography (ERCP) are invasive pro-
cedures not suitable for screening and diagnostic purposes.
2.1.7. Hepatobiliary scintigraphy
Hepatobiliary scintigraphy with iminodiacetic acid deriva-
tives can document a typical picture of biliary drainage
impairment, with dilation of intra- and extra-hepatic bile ducts
and delayed biliary excretion and intestinal appearance of the
tracer [35]. Scintigraphy can document time-related progres-
sion of liver disease and has been employed to monitor the
response to treatment with UDCA [18].
2.2. Diagnostic criteria of CFLD
The presence of CFLD should be considered if at least two
of the following variables are present (Fig. 1):
• Abnormal physical examination:
– Hepatomegaly deﬁned as an increased liver span relative
to age or as a liver edge palpable more than 2 cm below
the costal margin on the mid-clavicular line, conﬁrmed
by ultrasonography (Table 3). A prominent left lobe
palpable in the epigastrium is often noted in cases of
multilobular cirrhosis.
– And/or splenomegaly, conﬁrmed by US (Table 3).
• Abnormalities of liver function tests deﬁned as an increase
of transaminases (AST and ALT) and GGT levels above the
upper normal limits at least at 3 consecutive determinations
over 12 months after excluding other causes of liver disease
(Table 2).
• Ultrasonographic evidence of liver involvement (increased
and/or heterogeneous echogenicity, irregular margins,
Fig. 1. Flow chart for the investigation and management of CF-associated
liver disease. Abbreviations: ALT, alanine transaminase; ALP, alkaline phos-
phatase; AST, asparate transaminase; CFLD, Cystic Fibrosis-associated liver
disease; GGT, gamma glutamyl transpeptidase; LD, liver disease; PHT,
portal hypertension; UDCA, ursodeoxycholic acid; US, ultrasonography.
nodularity) or portal hypertension (splenomegaly, in-
creased thickness of the lesser omentum, spontaneous
splenorenal anastomosis, large collateral veins, ascites) or
biliary abnormalities (bile duct dilatation).
• A liver biopsy may be indicated if there is diagnostic
doubt.
Some patients with CFLD only have persistent abnormal
liver function tests with hepatomegaly and/or mild abnormal-
ities on US (increased and/or heterogeneous echogenicity),
Table 3
Upper limits of liver span measured at midclavicular line and upper limits of
spleen length measured at US in the longitudinal coronal plane according to
age
Age Liver span (cm)* Spleen length (cm)**
At birth 5.5 6
At 1 year 6.0 7
At 3 year 7.0 9
At 5 year 8.0 9.5
At 12 year 9.0 11.5
Adult Up to 12 Up to 13
*From Lawson et al. [36]; **from Rosenberg et al. [37].
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while others have cirrhosis with or without portal hyperten-
sion. CFLD severity and related complications are clearly
different between these groups. Therefore, both clinically and
for study purposes, it might be useful to make a distinction
between severe CFLD, i.e. those patients with cirrhosis and/or
portal hypertension, and other patients with CF-related liver
disease.
2.3. Recommendations
2.3.1. Screening for CFLD
Annual screening is recommended with:
• Abdominal examination by a gastroenterologist;
• Biochemical evaluation (AST, ALT, GGT, ALP, Prothrom-
bin time, platelets).
• Abdominal US with CT or MR imaging if concern exists
about the nature of liver lesions or biliary tract involvement
(such as sclerosing cholangitis).
2.3.2. Recommendations for starting ursodeoxycholic acid
The objective of UDCA treatment is to delay the progres-
sion of the disease and so treatment should be started as soon
as the diagnosis of CFLD is made (Fig. 1), although there
are no data on long-term outcomes such as death or need for
liver transplantation [38]. A daily dose of 20 mg/kg is initially
recommended [17]. A therapeutic schedule based on multiple
divided doses (at least twice/day) seems to be more effective
because of incomplete intestinal absorption [39]. Evaluation
of indices of cholestasis and cytolysis should be performed 3
and 6 months from initiation of therapy to test for the efﬁcacy
of UDCA and the dose should be increased if necessary.
Therapeutic drug monitoring for optimizing the dosage or
to assess adherence to UDCA would require assessment of
biliary enrichment with UDCA, which is not available on a
routine basis. Although serum UDCA may be analyzed by
gas liquid chromatography-mass spectrometry (GLC-MS), the
target range level is not deﬁned.
3. Follow-up of CFLD
All CF patients with CFLD need annual follow-up by
gastroenterologists or hepatologists in order to evaluate the
progression to cirrhosis, and screen for the development of
portal hypertension and other complications.
• All patients with cirrhosis and splenomegaly and/or signs
of hypersplenism should be screened for esophageal
varices (EV) at diagnosis by means of upper gastroin-
testinal (GI) endoscopy. If normal, it should be repeated
every 2–3 years. Once EV have developed, it is prudent
to perform an upper GI endoscopy once a year and treat
large varices (see management of PHT below). Any sign
suggestive of possible GI bleeding (anemia, microcytosis,
chronic iron depletion) should also prompt an upper GI
endoscopy. Some patients may develop rectal varices and
present with rectal bleeding.
• Other complications related to portal hypertension also
need annual screening:
– Hepatopulmonary syndrome results from dilatation of
intrapulmonary capillaries leading to a functional right
to left shunt and hypoxemia. Oxygen saturation should
be monitored in the supine and upright position: a
signiﬁcant decrease in oxygen saturation (>5%) when
the patient moves from a supine to an upright posi-
tion (called orthodeoxia) is suggestive of the diagnosis.
Proof of intrapulmonary capillary dilatation may be ob-
tained by means of contrast enhanced (bubble) echocar-
diography or technetium 99-labelled macro aggregated
albumin scintigraphy [40].
– Pulmonary arterial hypertension (i.e. portopulmonary
syndrome) is easily detected by echocardiography [41].
• Thrombocytopenia and leucopenia resulting from hyper-
splenism do not require any speciﬁc therapy. There is no
rationale for platelet transfusions unless there is intractable
bleeding, invasive procedures or surgery, neither for the use
of granulocyte growth factors in cases of severe leucopenia.
• Diagnosis of early signs of liver failure is more difﬁcult as
hepatic function is retained until the terminal phase. Pro-
thrombin time (PT) and coagulation factors should be mea-
sured at least once a year to detect early signs of liver failure.
A prolonged PT (above 13.5 seconds or decreased PT ac-
tivity below 70% of normal) and a decrease in cofactors are
however, non-speciﬁc markers of liver failure. A prominent
decrease in coagulation factor V compared to other cofac-
tors is often noted in patients with a large splenomegaly,
possibly as a result of intrasplenic consumption. An iso-
lated decrease in cofactors VII, X and II suggest vitamin K
deﬁciency that should be corrected with oral or intramus-
cular vitamin K supplementation. Liver failure should be
considered if PT and coagulation cofactors VII, X and II
remain decreased despite vitamin K supplementation.
• In patients with cirrhosis, it is appropriate to perform
an ultrasound scan of the liver and to measure alpha
fetoprotein levels annually in order to monitor the possible
development of hepatocellular carcinoma [42,43].
4. Management of esophageal varices
Whilst liver failure is uncommon in the paediatric popu-
lation, management of long-term complications of cirrhosis
should focus on control of bleeding and on variceal decom-
pression.
Screening for and treating large varices in adults with
cirrhosis without a history of bleeding is recommended by
recent guidelines of the American Board of Gastroenterology,
which are similar to European guidelines [44]. Recommen-
dations suggest the use of non selective β-blockers as ﬁrst
step therapy in patients with grade 2 or 3 varices, band
ligation in cases of β-blockade contraindication or failure
(secondary prophylaxis) and the placement of a transjugular
intrahepatic portosystemic shunt (TIPS) in cases of ligation
failure (tertiary prophylaxis). No clear recommendations with
respect to prevention of GI bleeding have been published
in CF patients. CF patients clearly differ from others with
respect to lung disease that may contraindicate β-blockers.
S34 D. Debray et al. / Journal of Cystic Fibrosis Volume 10 Suppl 2 (2011) S29–S36
However, repeated general anaesthesia required for screening
of therapeutic endoscopic procedures may also reduce lung
function and predispose to infection unless managed with
intravenous antibiotics and vigorous physiotherapy.
The efﬁcacy and safety of β-blockade in preventing
variceal bleeding has not been evaluated among CF patients.
Sclerotherapy has for a long time been the only means of
treating bleeding esophageal varices. Because sclerotherapy
carries a risk of bleeding during or following the procedure
and because repeated general anaesthesia might cause de-
terioration of lung function, it has not been recommended
in CF patients as a primary prophylaxis. Band ligation is a
more effective therapy to prevent GI bleeding in adults [45],
but studies are needed in the CF population to assess the
long-term efﬁcacy and possible impact of repeated general
anaesthesia on lung function.
TIPS has been employed for portal decompression in pa-
tients with recurrent bleeding, both as a long-term therapy
for portal hypertension or as a bridge for liver transplantation
[46].
Alternatively, surgical portal systemic shunting has been
successfully performed in selected CF patients with preserved
liver function and without severe lung insufﬁciency, allowing
prolonged post-operative survival [4,47]. However, potential
complications include development of hepatic encephalopathy
and acute liver failure.
Partial splenectomy has also been advocated as a therapy
for portal hypertension in CF patients who present with
large splenomegaly and profound thrombopenia related to
hypersplenism [48], but accelerated decline in lung function
and unsuccessful prevention of variceal bleeding have been
reported [4,49,50] and therefore this is not recommended.
Although practice differs among different centers, common
recommendations are:
• Contraindication of salicylic acid and non-steroid anti-
inﬂammatory drugs if there is evidence of CFLD, to
prevent bleeding from portal hypertensive gastropathy and
GI varices
• Vaccination against hepatitis A and B
• Treatment of large varices with red wale signs (grade 2
and more) to prevent bleeding: band ligation appears a
preferable alternative to sclerotherapy to be indicated as
ﬁrst line therapy and should be repeated until varices are
eradicated.
4.1. Nutritional support
The development of liver disease may further exacerbate
malnutrition, a common complication of CF, by increasing fat
malabsorption and protein loss.
The following dietary management is recommended:
• Increase energy intake to 150% of Estimated Average
Requirement (or Recommended Daily Allowance), which
may be preferentially achieved by increasing the per-
centage of fat and only rarely by adding carbohydrate
supplements, such as glucose polymers, due to the risk of
developing CF-related diabetes mellitus [51].
• Increase the proportion of fat to 40–50% of the energy con-
tent of the feed or diet, with supplementation in medium
chain triglycerides and special attention to polyunsaturated
fatty acids.
• Provide protein supplements to ensure an intake of 3 g/kg/
day in patients without signs of liver failure.
• Ensure that sufﬁcient pancreatic enzymes are prescribed to
allow optimal absorption of long-chain triglycerides and
essential fatty acids.
• Avoid salt supplementation in CF patients with cirrhosis
and PHT that may precipitate the development of ascites.
• Prescribe fat soluble vitamin supplements: high oral doses
of vitamin A (5,000–15,000 international units daily),
vitamin E (alpha tocopherol 100–500 mg daily) and
vitamin D (alpha calcidiol 50 ng/kg to maximum of 1 μg).
Vitamin K is sometimes required (1–10 mg daily). PT
and cofactors need to be carefully monitored to prevent
deﬁciency. Supplementation with vitamin A, vitamin E and
vitamin D should be also carefully monitored with plasma
levels to prevent toxicity or deﬁciencies.
In children in whom anorexia is a problem, enteral
nasogastric feeding may be required to ensure adequate
caloric intake when awaiting a liver transplant. Gastrostomy
feeding is not recommended in children with advanced liver
disease, varices or portal gastropathy because of the risk of
gastric haemorrhage.
5. Recommendations for referral to a transplant center
Selection criteria for orthotopic liver transplantation (OLT)
and timing in CF have not yet been established, how-
ever indications differ from other liver diseases in which
chronic hepatic failure is the main indication. In CF, other
extra-hepatic parameters are important considerations, which
include progressive deterioration of nutritional status de-
spite nutritional support, deterioration of pulmonary function
and recurrent respiratory multi-resistant bacterial infections,
leading to frequent hospital admissions. There is increasing
evidence that poor growth and nutritional status are associated
with deterioration of lung function and a high post-transplant
mortality rate. The issue of timing is clinically relevant and
two scoring systems evaluating the need for transplantation
are available, both of which include parameters of nutritional
status [52,53].
Clear indications for liver transplantation in CF liver
disease are:
• progressive hepatic dysfunction (falling albumin <30 g/l;
increasing coagulopathy, not corrected by vitamin K)
• development of ascites and jaundice
• intractable variceal bleeding which is not controlled by
conventional means
• hepatopulmonary and portopulmonary syndromes
• severe malnutrition, unresponsive to intensive nutritional
support
• deteriorating quality of life related to liver disease
• deteriorating pulmonary function (FEV1/FVC <50%).
The transplant assessment should evaluate pulmonary and
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cardiac function in order to establish whether liver trans-
plantation alone is required or a combined heart/lung/liver
transplant is more appropriate [54].
A few patients beneﬁt from early and elective OLT, before
development of signiﬁcant and irreversible pulmonary and
nutritional deterioration [52,53,55]. Stabilization and even
amelioration of lung function post transplantation has been
reported, arguing in favour of early liver transplantation.
Recently, a poll among European CF and Transplant Centers
was carried out in order to obtain information on current
practice and outcome for liver transplant in CF patients
in Europe: in the majority of cases, transplantation was
performed before development of end-stage liver disease [56].
Although patient and graft survival compare favourably with
those of liver transplantation for indications other than CF,
the risk of chronic liver graft rejection, lymphomas, renal
dysfunction and diabetes should be balanced against the
potential beneﬁts of transplantation on lung function and
nutritional status [57,58]. Indeed, recent studies suggest that
OLT may not improve long-term survival in patients with
CF and signiﬁcant portal hypertension, but does improve
quality of life [59]. Given improved management of the
complications of portal hypertension, liver transplantation
should be reserved for CF patients who have evidence of
hepatocellular dysfunction in addition to portal hypertension
or those with rapid deterioration of pulmonary function.
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